Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Nasopharyngeal Carcinoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Hematologic Neoplasms 2Plasmacytoma 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

Cyclophosphamide 27Rituximab 20Etoposide 14Cytarabine 13Melphalan 11Vincristine 10fludarabine 9Prednisone 9Doxorubicin 9Busulfan 8Peripheral Blood Stem Cell Transplantation 7Radiotherapy 6Filgrastim 6Cyclosporine 6Bendamustine Hydrochloride 6fludarabine phosphate 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Mycophenolic Acid 5Cisplatin 5tositumomab I-131 4ibritumomab tiuxetan 4Ifosfamide 4Dexamethasone 4Carmustine 4relmacabtagene autoleucel 3Thiotepa 3Indium 3Immunotherapy, Adoptive 3Gemcitabine 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Non-Hodgkin × CF regimen × Clear all
NCT05370547 2024-03-06

Chidamide Bridging for CAR-T Therapy

Chinese PLA General Hospital

Phase 1/2 Unknown
120 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT04666168 2020-12-14

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
200 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡